Sartorius Stedim Biotech presents new crossflow filtration system for process development
The ideal solution for scaling studies and low volume ultra- and diafiltration operations.
Sartorius Stedim Biotech (SSB) has launched SARTOFLOW Smart, the smart and easy benchtop crossflow system for optimized ultra- and diafiltration applications. It can ideally be used in many downstream processes, such as purification of vaccines, monoclonal antibodies and recombinant proteins. The system is suitable for flexible use in laboratory environments for process development and clinical trials as well as for cGMP environments.
The brand new system is equipped with a low shear 4-piston membrane pump that enables highest product yields to be achieved. In addition the pump provides a wide range of flow rates allowing to choose between membrane surface areas from 50 cm² to as much as 0.14 m².
The crossflow system is supplied with SSB’s intuitive and easy to use DCU-4 control unit, which, when combined with the company’s BioPAT SCADA, MFCS-4 software, provides data logging and export. Its touchscreen offers instant access to all critical process parameters and displays control and alarm functions. A logbook function stores alarms, set points and user logs.
The SARTOFLOW family of crossflow systems shares an unique operation design with a 7” touchscreen that supports the operator with interactive prompts for easy guidance through entire process sequences. Users can select predefined parameters to automatically run sequences for concentration, diafiltration, rinsing, filling, draining, flushing steps and tare functions.
An optional peristaltic diafiltration pump is available to load product or buffer as a discrete process step. Furthermore, several options are available to customize the system according to specific requirements. For example, a conductivity, pH or temperature probe can be installed in the recirculation vessel. The system can also be upgraded in the case of changing process requirements.
“SARTOFLOW Smart is a milestone development in the landscape of small crossflow systems. It combines outstanding technology with options that are normally only available with process systems. With an exceptionally wide working range of membrane surface areas, the system is the perfect tool for both R&D optimization trials and cGMP production,” stated Dr. Marc Jenke, expert for benchtop crossflow filtration systems at Sartorius Stedim Biotech.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance